← Eichor
Condition: Allogeneic Hematopoietic Cell Transplantation Hct Synced from ClinicalTrials.gov · July 29, 2026

Recruiting studies: Allogeneic Hematopoietic Cell Transplantation Hct

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

Intraoral Photobiomodulation Therapy to Prevent Oral Mucositis in Patients Undergoing Hematopoietic Cell Transplantation
NA · 1 location(s) · Dana-Farber Cancer Institute · NCT05335434Momelotinib During and After HCT in Myelofibrosis
Phase 1 · 1 location(s) · Massachusetts General Hospital · NCT07104799Trial for Patients w/ Advanced Hematologic Malignancies Undergoing Allogeneic HCT
Phase 1 · 1 location(s) · Stanford University · NCT06551584Trial of Allogeneic Reduced-Intensity, HLA-Haploidentical Allogeneic Hematopoietic Cell Bone Marrow Transplantation Foll
Phase 1/Phase 2 · 1 location(s) · National Cancer Institute (NCI) · NCT05470491Vitamin A and D Supplementation in Allogeneic HCT
Phase 2 · 1 location(s) · St. Petersburg State Pavlov Medical University · NCT06508099Enasidenib (AG-221) Maintenance Post Allogeneic HCT in Patients With IDH2 Mutation
Phase 2 · 2 location(s) · City of Hope Medical Center · NCT03728335A Phase 3 Trial to Compare IV BCV Versus IV CDV for Treatment of Adenovirus Infection After Allo-HCT
Phase 3 · 81 location(s) · SymBio Pharmaceuticals · NCT07387367Mocravimod as Adjunctive and Maintenance Treatment in AML Patients Undergoing Allo-HCT
Phase 3 · 111 location(s) · Priothera SAS · NCT05429632Ivosidenib as Post-HSCT Maintenance for AML
Phase 2 · 6 location(s) · Massachusetts General Hospital · NCT06707493Sorafenib Relapase Prophylaxis After HCT With PTBCy Regimen
Phase 2 · 1 location(s) · St. Petersburg State Pavlov Medical University · NCT06532084Ziftomenib Maintenance Post Allo-HCT
Phase 1 · 2 location(s) · Massachusetts General Hospital · NCT06440135Combination Chemotherapy (FLAG-Ida) Followed Immediately by Reduced-Intensity Total Body Radiation Therapy and Donor Hem
Phase 2 · 1 location(s) · Fred Hutchinson Cancer Center · NCT07046078Donor Virus-Specific CMV or AdV CTL to Treat CMV or AdV Reactivation or Disease After Solid Organ or HCT
EARLY_Phase 1 · 2 location(s) · Sumithira Vasu · NCT03665675A Study of T-Cell Receptor Engineered Donor T Cells in Subjects Undergoing Allogeneic Peripheral Blood Stem Cell Transpl
Phase 3 · 26 location(s) · TScan Therapeutics, Inc. · NCT07702578Dapagliflozin in Allo-HCT for aGVHD
Phase 2 · 1 location(s) · The First Affiliated Hospital of Soochow University · NCT06626737Blinatumomab After TCR Alpha Beta/CD19 Depleted HCT
Phase 2 · 1 location(s) · Medical College of Wisconsin · NCT04746209A Study of Immune Suppression Treatment for People With Sickle Cell Disease or β-Thalassemia Who Are Going to Receive an
Phase 2 · 6 location(s) · Memorial Sloan Kettering Cancer Center · NCT05736419Pralatrexate With Bendamustine and Total-Body Irradiation Followed by Donor Stem Cell Transplant for the Treatment of Re
Phase 1/Phase 2 · 1 location(s) · Fred Hutchinson Cancer Center · NCT07225985HA-1 T TCR T Cell Immunotherapy for the Treatment of Patients With Relapsed or Refractory Acute Leukemia After Donor Ste
Phase 1 · 1 location(s) · Fred Hutchinson Cancer Center · NCT03326921The EndRAD Trial: Eliminating Total Body Irradiation (TBI) for NGS-MRD Negative Children, Adolescents, and Young Adults
Phase 2 · 24 location(s) · Pediatric Transplantation & Cellular Therapy Consortium · NCT03509961Vulvovaginal Graft-versus-Host Disease: Diagnosis and Microbiome Evaluation
Phase N/A · 1 location(s) · Case Comprehensive Cancer Center · NCT06649201A Phase 3 Study of Tabelecleucel for Participants With Epstein-Barr Virus-Associated Post-Transplant Lymphoproliferative
Phase 3 · 71 location(s) · Pierre Fabre Medicament · NCT03394365A Study of Ruxolitinib for Preventing Graft-Versus-Host Disease in People With a Hematologic Malignancy Who Will Receive
Phase 2 · 7 location(s) · Memorial Sloan Kettering Cancer Center · NCT07359859MRD-guided Maintenance Post-HCT: Gilteritini vs Sorafenib
Phase 3 · 2 location(s) · The First Affiliated Hospital of Soochow University · NCT07463651Post-transplantation Maintenance Therapy With Cidabenamide in Patients With Intermediate/High-risk AML
Phase 2 · 5 location(s) · Institute of Hematology & Blood Diseases Hospital, China · NCT07304232
Look up another condition
Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.